Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies.
Leuk Lymphoma
; 61(14): 3440-3450, 2020 12.
Article
in English
| MEDLINE | ID: covidwho-1066113
ABSTRACT
Patients with hematological malignancies with immunodeficiency are at high risk for SARS-CoV-2 infection. We retrospective summarized clinical characteristics of coronavirus disease 2019 (COVID-19) inpatients with hematological malignancies, shared treatment experiences, and analysis prognostic factors. Fourteen patients were enrolled. The median duration of viral shedding was 27.5 days in survivors. The median duration of time to death was 13 days in non-survivors. Non-survivors tend to present lower neutrophil count, more imaging finding of bilateral diffuse patch opacities, more undergoing intensive chemotherapy or immunosuppression. Laboratory and image findings were atypical and diverse. COVID-19 inpatients undergoing intensive chemotherapy or immunosuppression might have increased risk of death. The diagnostic value of specific antibody detection is limited. Therefore, adult COVID-19 inpatients with hematological malignancies present atypical, severe symptoms, decreased virus clearance ability, abnormal antibody response and poor outcome. During the epidemic, the pros and cons need to be carefully weighed while selecting the treatment methods.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hematologic Neoplasms
/
SARS-CoV-2
/
COVID-19
/
Inpatients
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
/
Qualitative research
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
/
Young adult
Language:
English
Journal:
Leuk Lymphoma
Journal subject:
Hematology
/
Neoplasms
Year:
2020
Document Type:
Article
Affiliation country:
10428194.2020.1808204
Similar
MEDLINE
...
LILACS
LIS